{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:40:47Z","timestamp":1783104047485,"version":"3.54.6"},"reference-count":55,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain underexplored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single-cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. By generating high-resolution Micro Capture-C data in primary patient samples, we identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may be a mechanism that drives transcriptional heterogeneity in cancer more generally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024028019","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:32:53Z","timestamp":1753821173000},"page":"2073-2087","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1407","authenticated-orcid":false,"given":"Alastair L.","family":"Smith","sequence":"first","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Denny","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-5260","authenticated-orcid":false,"given":"Catherine","family":"Chahrour","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Sharp","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Arachi","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7314-3319","authenticated-orcid":false,"given":"Ana M.","family":"Dopico-Fernandez","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-7349","authenticated-orcid":false,"given":"Natalina","family":"Elliott","sequence":"additional","affiliation":[{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe R.","family":"Harman","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"3Dark Blue Therapeutics Ltd, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jackson","sequence":"additional","affiliation":[{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Geng","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Smith","sequence":"additional","affiliation":[{"name":"5Trinity College, University of Dublin, Dublin, Ireland"},{"name":"6Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"7Children's Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-1599","authenticated-orcid":false,"given":"Jonathan","family":"Bond","sequence":"additional","affiliation":[{"name":"6Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"7Children's Health Ireland at Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-6397","authenticated-orcid":false,"given":"Irene","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-1656","authenticated-orcid":false,"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[{"name":"8Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-6763","authenticated-orcid":false,"given":"Nicholas T.","family":"Crump","sequence":"additional","affiliation":[{"name":"9Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-4357","authenticated-orcid":false,"given":"James O. J.","family":"Davies","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"10Radcliffe Department of Medicine, Oxford National Institute of Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-5748","authenticated-orcid":false,"given":"Anindita","family":"Roy","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2Department of Paediatrics, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-4271","authenticated-orcid":false,"given":"Thomas A.","family":"Milne","sequence":"additional","affiliation":[{"name":"1Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2025102311222379400_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41580-018-0028-8","article-title":"Eukaryotic core promoters and the functional basis of transcription initiation","volume":"19","author":"Haberle","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025102311222379400_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-024-00710-6","article-title":"Enhancer selectivity in space and time: from enhancer-promoter interactions to promoter activation","author":"Yang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2025102311222379400_bib3","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.molmed.2021.07.012","article-title":"Enhancers in disease: molecular basis and emerging treatment strategies","volume":"27","author":"Claringbould","year":"2021","journal-title":"Trends Mol Med"},{"issue":"6215","key":"2025102311222379400_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1126\/science.1259037","article-title":"Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"issue":"6713","key":"2025102311222379400_bib5","doi-asserted-by":"crossref","first-page":"eadk9217","DOI":"10.1126\/science.adk9217","article-title":"Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers","volume":"385","author":"Sundaram","year":"2024","journal-title":"Science"},{"issue":"5","key":"2025102311222379400_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/2643-3230.BCD-23-0211","article-title":"Oncogenic enhancers in leukemia","volume":"5","author":"Mulet-Lazaro","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025102311222379400_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41420-025-02366-3","article-title":"Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies","volume":"11","author":"Yang","year":"2025","journal-title":"Cell Death Discov"},{"issue":"3","key":"2025102311222379400_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ng1966","article-title":"Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome","volume":"39","author":"Heintzman","year":"2007","journal-title":"Nat Genet"},{"issue":"50","key":"2025102311222379400_bib9","doi-asserted-by":"crossref","first-page":"21931","DOI":"10.1073\/pnas.1016071107","article-title":"Histone H3K27ac separates active from poised enhancers and predicts developmental state","volume":"107","author":"Creyghton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6409","key":"2025102311222379400_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1126\/science.aau0320","article-title":"Developmental enhancers and chromosome topology","volume":"361","author":"Furlong","year":"2018","journal-title":"Science"},{"key":"2025102311222379400_bib11","unstructured":"Blood Cancer UK\n          . Acute lymphoblastic leukaemia (ALL) statistics. Accessed 4 August 2025. https:\/\/bloodcancer.org.uk\/understanding-blood-cancer\/leukaemia\/acute-lymphoblastic-leukaemia\/."},{"issue":"9","key":"2025102311222379400_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/jcm10091926","article-title":"Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia","volume":"10","author":"Inaba","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"2025102311222379400_bib13","doi-asserted-by":"crossref","first-page":"194564","DOI":"10.1016\/j.bbagrm.2020.194564","article-title":"MLL-rearranged infant leukaemia: a 'thorn in the side' of a remarkable success story","volume":"1863","author":"Rice","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"17","key":"2025102311222379400_bib14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2025102311222379400_bib15","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2025102311222379400_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc3634","article-title":"Survivors of childhood and adolescent cancer: life-long risks and responsibilities","volume":"14","author":"Robison","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2025102311222379400_bib17","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ijc.34634","article-title":"Quality of life of adolescent and adult survivors of childhood cancer in Europe-A systematic review","volume":"153","author":"Larsen","year":"2023","journal-title":"Int J Cancer"},{"issue":"5","key":"2025102311222379400_bib18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"7137","key":"2025102311222379400_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"issue":"1","key":"2025102311222379400_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/leu.2010.232","article-title":"Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients","volume":"25","author":"Bardini","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"2025102311222379400_bib21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/gcc.22090","article-title":"The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia","volume":"52","author":"Dobbins","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"2025102311222379400_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat Genet"},{"issue":"6","key":"2025102311222379400_bib23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","article-title":"Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis","volume":"104","author":"Agraz-Doblas","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2025102311222379400_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41375-021-01341-y","article-title":"Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics","volume":"36","author":"Candelli","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2025102311222379400_bib25","doi-asserted-by":"crossref","first-page":"194548","DOI":"10.1016\/j.bbagrm.2020.194548","article-title":"The molecular functions of common and atypical MLL fusion protein complexes","volume":"1863","author":"Takahashi","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"3","key":"2025102311222379400_bib26","doi-asserted-by":"crossref","first-page":"194503","DOI":"10.1016\/j.bbagrm.2020.194503","article-title":"MLL fusion proteins and transcriptional control","volume":"1863","author":"Slany","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"20","key":"2025102311222379400_bib27","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.2023020858","article-title":"A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features","volume":"142","author":"Bueno","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025102311222379400_bib28","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1038\/s41467-024-53399-8","article-title":"MLL oncoprotein levels influence leukemia lineage identities","volume":"15","author":"Janssens","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2025102311222379400_bib29","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1038\/s41467-023-40981-9","article-title":"MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia","volume":"14","author":"Crump","year":"2023","journal-title":"Nat Commun"},{"key":"2025102311222379400_bib30","doi-asserted-by":"crossref","first-page":"102191","DOI":"10.1016\/j.gde.2024.102191","article-title":"Chromatin and aberrant enhancer activity in KMT2A rearranged acute lymphoblastic leukemia","volume":"86","author":"Milne","year":"2024","journal-title":"Curr Opin Genet Dev"},{"issue":"7865","key":"2025102311222379400_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-021-03639-4","article-title":"Defining genome architecture at base-pair resolution","volume":"595","author":"Hua","year":"2021","journal-title":"Nature"},{"issue":"1","key":"2025102311222379400_bib32","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41467-019-09982-5","article-title":"CUT&Tag for efficient epigenomic profiling of small samples and single cells","volume":"10","author":"Kaya-Okur","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"2025102311222379400_bib33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-023-00817-8","article-title":"Determining chromatin architecture with Micro Capture-C","volume":"18","author":"Hamley","year":"2023","journal-title":"Nat Protoc"},{"issue":"11","key":"2025102311222379400_bib34","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/s41375-021-01209-1","article-title":"Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks","volume":"35","author":"Diedrich","year":"2021","journal-title":"Leukemia"},{"issue":"7345","key":"2025102311222379400_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature09906","article-title":"Mapping and analysis of chromatin state dynamics in nine human cell types","volume":"473","author":"Ernst","year":"2011","journal-title":"Nature"},{"issue":"2","key":"2025102311222379400_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"issue":"7243","key":"2025102311222379400_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature07829","article-title":"Histone modifications at human enhancers reflect global cell-type-specific gene expression","volume":"459","author":"Heintzman","year":"2009","journal-title":"Nature"},{"issue":"1","key":"2025102311222379400_bib38","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1038\/s41467-021-27270-z","article-title":"A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program","volume":"12","author":"Rice","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"2025102311222379400_bib39","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41587-019-0332-7","article-title":"Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia","volume":"37","author":"Granja","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2025102311222379400_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molcel.2010.05.011","article-title":"Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis","volume":"38","author":"Milne","year":"2010","journal-title":"Mol Cell"},{"issue":"6","key":"2025102311222379400_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccr.2010.04.012","article-title":"The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis","volume":"17","author":"Muntean","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"2025102311222379400_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2016.10.008","article-title":"Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia","volume":"30","author":"Lin","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"2025102311222379400_bib43","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/s41467-019-10844-3","article-title":"DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation","volume":"10","author":"Godfrey","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"2025102311222379400_bib44","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2025102311222379400_bib45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"7954","key":"2025102311222379400_bib46","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"2025102311222379400_bib47","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.1038\/ncomms12983","article-title":"Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity","volume":"7","author":"Ooi","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2025102311222379400_bib48","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1038\/s41467-022-35135-2","article-title":"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential","volume":"13","author":"Kneppers","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"2025102311222379400_bib49","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/s41591-018-0091-x","article-title":"Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer","volume":"24","author":"Patten","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2025102311222379400_bib50","first-page":"539","article-title":"Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions","volume":"34","author":"Joosten","year":"2024","journal-title":"Genome Res"},{"issue":"6159","key":"2025102311222379400_bib51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1242510","article-title":"Extensive variation in chromatin states across humans","volume":"342","author":"Kasowski","year":"2013","journal-title":"Science"},{"key":"2025102311222379400_bib52","unstructured":"Leibniz Institute, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH\n          . SEM. Accessed 4 August 2025. https:\/\/www.dsmz.de\/collection\/catalogue\/details\/culture\/ACC-546."},{"key":"2025102311222379400_bib53","unstructured":"Leibniz Institute, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH\n          . RS4;11. Accessed 4 August 2025. https:\/\/www.dsmz.de\/collection\/catalogue\/details\/culture\/ACC-508."},{"issue":"6","key":"2025102311222379400_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/onc.2008.443","article-title":"Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2","volume":"28","author":"Bach","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"2025102311222379400_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.celrep.2016.12.054","article-title":"MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia","volume":"18","author":"Kerry","year":"2017","journal-title":"Cell Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024028019\/2417598\/blood_bld-2024-028019-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024028019\/2417598\/blood_bld-2024-028019-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:22:33Z","timestamp":1761232953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/17\/2073\/546394\/Enhancer-heterogeneity-in-acute-lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":55,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,10,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028019","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.08.627394","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,23]]},"published":{"date-parts":[[2025,10,23]]}}}